U.S. flag

An official website of the United States government

NM_000492.4(CFTR):c.1209+6A>G AND not specified

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Nov 29, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001192459.1

Allele description [Variation Report for NM_000492.4(CFTR):c.1209+6A>G]

NM_000492.4(CFTR):c.1209+6A>G

Gene:
CFTR:CF transmembrane conductance regulator [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
7q31.2
Genomic location:
Preferred name:
NM_000492.4(CFTR):c.1209+6A>G
HGVS:
  • NC_000007.14:g.117542114A>G
  • NG_016465.4:g.81331A>G
  • NM_000492.4:c.1209+6A>GMANE SELECT
  • LRG_663t1:c.1209+6A>G
  • LRG_663:g.81331A>G
  • NC_000007.13:g.117182168A>G
  • NM_000492.3:c.1209+6A>G
  • NM_000492.4:c.1209+6A>G
Links:
dbSNP: rs749054857
NCBI 1000 Genomes Browser:
rs749054857
Molecular consequence:
  • NM_000492.4:c.1209+6A>G - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001360596Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Nov 29, 2019)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001360596.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Variant summary: CFTR c.1209+6A>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 8e-06 in 249772 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1209+6A>G in individuals affected with Cystic Fibrosis and no experimental evidence demonstrating its impact on protein function have been reported. However, a database, sickkids, reports that this mutation "was found in anItalian adult patient with idiopatic infertility; moreover detected in a 50 years old Italian man, also carrying R31C, with BPCO, Bronchiectasis, lung infection by Pseudomonas aeruginosa and sweat chloride 36mEq/l. He is PS." A ClinVar submission (evaluation after 2014) cites the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024